Benitec Biopharma Reports 100% Response In BB-301 OPMD Trial For Oculopharyngeal Muscular Dystrophy (OPMD); Gains Fast Track designation

Benitec Biopharma Inc. (NASDAQ: BNTC), a clinical-stage biotechnology company focused on developing genetic medicines through its proprietary “Silence and Replace” DNA-directed RNA interference (ddRNAi) platform, announced positive interim results from its Phase 1b/2a clinical trial evaluating BB-301 for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). All six patients in Cohort 1 showed significant and sustained improvements in multiple swallowing-related clinical measures, including dysphagic symptom burden, swallowing efficiency, and pharyngeal closure. Impressively, every patient met the formal statistical response criteria, achieving a 100% response rate. Based on these encouraging results, the U.S. FDA granted Fast Track designation to BB-301, which had previously received Orphan Drug status from both the FDA and EMA.

Benitec’s CEO, Dr. Jerel A. Banks, emphasized that OPMD-related dysphagia is a severe, life-threatening complication affecting the majority of OPMD patients. He noted that BB-301’s demonstrated clinical benefit highlights the potential of this gene therapy to address an urgent unmet medical need. The company views the FDA’s Fast Track designation as validation of both the therapy’s promise and the strength of its clinical data.

The trial’s interim data, gathered from 3 to 12 months of post-treatment follow-up, evaluated multiple outcome measures combining patient-reported results, imaging-based assessments, and functional swallowing tests. These comprehensive evaluations showed consistent and meaningful clinical improvements, reinforcing BB-301’s potential to become the first disease-modifying gene therapy for OPMD. The company plans to advance the program toward pivotal trials following continued regulatory collaboration.